CLINICAL RESEARCH OF INFECTIONS IN TRANSPLANTATION

描述：(改编自申请者S摘要)一大障碍限制 人类同种异体移植的成功与否与移植相关因素密切相关。 严重的并发症。虽然在过去的一年中取得了重大进展 十年来对反式-阿司匹林的发病机制和最佳治疗方法的阐明 植物感染并发症，一些感染仍在继续引起SIG-- 移植受者的显著发病率和死亡率。申请人是 这一领域的活跃临床研究人员，并已确定了两个主要的 需要进行额外研究以克服这些影响的领域 感染。这些措施包括解决贝塔疱疹家族的作用 病毒(CMV、HHV-6和HHV-7)和EB病毒(EBV)诱导的后遗症 移植淋巴增生性疾病(PTLD)。这项临床研究是一项 为培养未来的临床医生研究员提供了肥沃的土壤 多学科互动：免疫学、诊断病毒学和移植计划 治疗药物。通过这项裁决，申请人正在寻求支持 获得临床研究特定方面的额外培训，包括 以病人为中心的正规研究课程，与临床的互动 研究单位(GCRC)、GMP设施和免疫疗法方面的额外培训 移植患者的慢性病毒感染。申请者正在寻求 在一个临床研究小组内，支持解决提到的两个问题 移植中传染病的重点领域以及未来的哪些领域 临床医生调查员将接受正式培训。其具体目的是 将继续进行的应用包括：i)研究HHV-6和 器官移植受者HHV-7感染情况及其与其他疾病的相互作用 Nistic病毒感染(CMV、EBV、乙肝病毒和丙型肝炎病毒)。二)界定临床 EBV病毒载量在EBV-PTLD预防和治疗中的价值 验证细胞免疫疗法防治猪瘟的可行性。 EBV幼稚实体器官移植受者的EBVPTLD评估。总而言之， 这一奖项将使我们能够通过严格的以患者为导向的重新 搜索，移植感染并发症的两个领域，这限制了 成功的人体移植。此外，它还将有助于培养一名 一批未来的临床医生研究人员，他们将进一步推动这一进程- 临床医学的新领域。

DESCRIPTION: (Adapted from Applicant s Abstract) One major barrier limiting the success of human allotransplantation is the transplantation related infec- tious complications. While significant progress has been made in the last decade in elucidating the pathogenesis and the optimal management of trans- plant infectious complications, a number of infections continue to cause sig- nificant morbidity and mortality in the transplant recipient. The applicant is an active clinical investigator in this field and has identified two major areas in which additional research is required to overcome the impact of these infections. These include addressing the role of the family of beta-herpes viruses (CMV, HHV-6, and HHV-7) and Epstein Barr Virus (EBV) induced post- transplant lymphoproliferative disease (PTLD). This clinical research is a fertile ground for training of future clinician investigators as it conveys multidisciplinary interaction: immunology, diagnostic virology, and transplan- tation medicine. Through this award, the applicant is seeking the support to obtain additional training in specific aspects of clinical research including formal courses in patient-oriented research, interactions with the clinical research unit (GCRC), GMP facilities, and additional training in immunotherapy of chronic viral infections in transplant patients. The applicant is seeking the support to, within a clinical research group, address the two mentioned focused areas in infectious diseases in transplantation and in which future clinician investigators will be formally trained. The specific aims that this application will pursue include: I) Study the clinical relevance of HHV-6 and HHV-7 in organ transplant recipients and their interaction with other opportu- nistic viral infections (CMV, EBV, HBV, and HCV). II) Define the clinical value of EBV viral load for the prevention and management of EBV-PTLD, and test the feasibility of cell-based immune therapy for the prevention and trea- tment of EBVPTLD in EBV naive solid organ transplant recipients. Altogether, this award will allow us to address, through rigorous patient-oriented re- search, two areas of transplant infectious complications, which are limiting success in human transplantation. Moreover, it will facilitate to train a cadre of future clinician investigators who will further advance this impor- tant field of clinical medicine.